Fig. 3. Response characteristics in patients with ALK-mutated or ALK-amplified neuroblastoma who are receiving lorlatinib as a single agent or in combination with topotecan/cyclophosphamide.
The three panels show response onset and duration by NANT criteria26 for patients treated with single-agent lorlatinib in cohorts A1 (≥12 months to <18 years), A2 (≥18 years) and B2 (<18 years, in combination with chemotherapy). The color of the bar represents the patient’s BOR; the length of the bar represents duration of response; and the tick mark represents time to best response. Patient 3 (A1, DL1) was the only patient with a germline ALK mutation. Patient 42 (enrolled in ongoing B1 lorlatinib monotherapy expansion) and patient 47 (enrolled in ongoing chemotherapy combination for ≥18 years of age) are not included in this evaluation. NE, not evaluable; Pt, patient.